Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 10/02/26
Gilead Sciences (GILD) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 09/30/26
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHFBusiness Wire • 09/17/26
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to KnowZacks Investment Research • 09/17/26
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin AmericaZacks Investment Research • 09/16/26
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV PreventionBusiness Wire • 09/16/26
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the CaribbeanBusiness Wire • 09/15/26
Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowZacks Investment Research • 09/14/26
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/10/26
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 09/08/26
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of MedicinesBusiness Wire • 09/08/26
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?The Motley Fool • 09/05/26
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?24/7 Wall Street • 09/04/26